First‑line treatment of metastatic renal cell carcinoma


MUDr. Igor Richter, Ph.D.1,2; doc. MUDr. Josef Dvořák, Ph.D.2; MUDr. Jiří Baroš1; MUDr. Vladimír Šámal3

1 Onkologické oddělení, Krajská nemocnice Liberec

2 Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha

3 Urologické oddělení, Krajská nemocnice Liberec



Renal cell cancer accounts 2-3 % of all cases of malignancy. Sunitinib and Pazopanib have so far been standard in first line treatment of metastatic renal cell cancer. In this review we discuss current first-line treatment options as new tyrosine kinase inhibitor cabozantinib, the new combination of immunotherapy (nivolumab plus ipilimumab), and combination of immunotherapy and tyrosine kinase inhibitor. With the growing therapeutic options, identification of new biomarkers will be crucial for optimizing first-line selection.


Key words

renal cell cancer, targeted treatment, first line treatment, immunotherapy



The full article is only available to subscribers

Become a regular subscriber to our Oncological Review...